Industries > Pharma > Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031

Forecasts by Therapeutic Area (Genetic Disorders, Neurological Disorders, Oncological Disorders, Metabolic Disorders, Ophthalmic Disorders, Other Therapeutic Areas), by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods), by Type (Ribozyme, DNAzyme, Anti-Gene, Other Type) AND Regional and Leading National Market Analysis PLUS Analysis of Leading ASO Therapeutics Companies AND COVID-19 Recovery Scenarios

PUBLISHED: 17 March 2021
PAGES: 368
PRODUCT CODE: PHA1120
SUBMARKET: Therapeutic Drugs

Clear
WOOCS 2.2.1
SKU: PHA1120 Categories: , Tags: ,

What is holding you back in the Antisense Oligonucleotide Therapeutics Business?
Antisense Oligonucleotide Therapeutics has great potential to target specific genes of interest in the context of precision medicine. Optimization of enhanced delivery, specificity, affinity, and nuclease resistance with reduced toxicity is underway in different disease context. This report gives a complete overview of antisense therapy and highlights its potential.

Our 360+ page report provides 275 tables, 191 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. See financial results, trends, opportunities, and revenue predictions. Much opportunity remains in this growing antisense oligonucleotide therapeutics market. Buy our report to see how to exploit these opportunities in the global market.

Forecasts to 2031 and other analyses reveal the commercial prospects
• In addition to revenue forecasting to 2031, our new study provides you with recent results, growth rates, and market shares.
• You find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), Porter’s Five Forces Analysis, product profiles and commercial developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect your industry. Access this report today.

To access the data contained in this document please email contactus@visiongain.com

Discover sales predictions for the global antisense oligonucleotide therapeutics market and submarkets
Over the last few years, the antisense oligonucleotide therapeutics has gained widespread attention due to the technological advancements and growth in understanding of the oligonucleotide therapeutics that inhabit the human body. Along with revenue prediction for the overall world market, there are 5 segmentations of the antisense oligonucleotide therapeutics market, with forecasts for 5 Therapeutic Area, 6 Route of Administration, 4 Types, each forecasted at a global, regional, and country level, along with COVID-19 impact recovery pattern analysis for all segments.

Leading companies and the potential for market growth
As per Visiongain analysis, global antisense oligonucleotide therapeutics market is estimated to be valued at US$xx billion in 2021 and is projected to reach at a market value of US$xx billion by 2031. We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

CTA

What Segments Are Covered in the Report?

Global Antisense Oligonucleotide Therapeutics Market by Therapeutic Area (COVID-19 Impact Recovery Analysis Covered)
• Genetic Disorders
• Neurological Disorders
• Oncological Disorders
• Metabolic Disorders
• Ophthalmic Disorders
• Other Therapeutic Areas

Global Antisense Oligonucleotide Therapeutics Market by Route of Administration (COVID-19 Impact Recovery Analysis Covered)
• Pulmonary Delivery
• Intravenous Injections
• Intradermal Injections
• Intraperitoneal Injections
• Topical Delivery
• Other Delivery Methods

Global Antisense Oligonucleotide Therapeutics Market by Type (COVID-19 Impact Recovery Analysis Covered)
• Ribozyme
• DNAzyme
• Anti-Gene
• Other Type

Global Antisense Oligonucleotide Therapeutics Market by Region (COVID-19 Impact Recovery Analysis Covered)
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East
• Africa

Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031
Need industry data? Please contact us today.

Which Key Players Are Leading the Global Market and how much Share do they Hold?
The global market for antisense oligonucleotide therapeutics is ascending and has made significant gains in treatments. The players in the antisense oligonucleotide therapeutics market are striving to tap the opportunities that this market offers. Companies are trying to explore the available prospects by adopting various strategies such as:
• Mergers and acquisitions.
• Product launches.
• Collaborations and partnerships.

Product approval is a major milestone facing all key competitors in the antisense oligonucleotide therapeutics market. Several strategies were implemented by key market players between 2015 and Jan 2021. There are over 50+ pharma companies involved in different aspects of antisense oligonucleotide therapeutics, including drugs, diagnostics, biomarkers, services, analyses and others.

How the Antisense Oligonucleotide Therapeutics Market report helps you? Buy this report to find answers for below questions and how can help you to stay updated
• What is the current size of the overall antisense oligonucleotide therapeutics market? How much will this market be worth from 2021 to 2031?
• How will market shares of the leading national markets change by 2031, and which geographical region will lead the market in 2031?
• Who are the leading companies and what are their activities, results, developments and prospects?
• What are some of the most prominent antisense oligonucleotide therapeutics currently in development?
• What are the main trends that will affect the world antisense oligonucleotide therapeutics market between 2021 and 2031?
• What are the main strengths, weaknesses, opportunities and threats for the market?
• What are the social, technological, economic and political influences that will shape that industry over the next ten years?
• How will the global antisense oligonucleotide therapeutics market evolve over the forecasted period, 2021 to 2031?
• Which therapies can succeed and what revenues could they generate to 2031?
• What will be the main commercial drivers for the antisense oligonucleotide therapeutics market from 2021 to 2031?
• How will market shares of prominent national markets change from 2021, and which countries will lead the market in 2031, achieving highest revenues and fastest growth?
• How will that industry evolve between 2021 and 2031, especially in R&D?

Top 10 Leading Players Profiled in the Report
• Ionis Pharmaceuticals, Inc.
• Sarepta Therapeutics, Inc.
• Biogen Inc.
• Alnylam Pharmaceuticals, Inc.
• Antisense Therapeutics Limited (ANP)
• Arrowhead Pharmaceuticals, Inc.,
• Enzon Pharmaceuticals, Inc.
• Bio-Path Holdings, Inc.
• GlaxoSmithKline PLC
• Geron Corporation (Geron)

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Antisense Oligonucleotide Therapeutics Market and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com

Buy our report today Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031: Forecasts by Therapeutic Area (Genetic Disorders, Neurological Disorders, Oncological Disorders, Metabolic Disorders, Ophthalmic Disorders, Other Therapeutic Areas), by Route of Administration (Pulmonary Delivery, Intravenous Injections, Intradermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods), by Type (Ribozyme, DNAzyme, Anti-Gene, Other Type) AND Regional and Leading National Market Analysis PLUS Analysis of Leading ASO Therapeutics Companies AND COVID-19 Recovery Scenarios. Avoid missing out by staying informed – order our report now.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

Download sample pages

Complete the form below to download your free sample pages for Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031


Download sample pages

Complete the form below to download your free sample pages for Antisense Oligonucleotide (ASO) Therapeutics Market Report 2021-2031


Latest Pharma news

Visiongain Publishes Top 50 Pharmaceutical Wholesale & Distribution Companies 2021

Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

04 August 2021

READ

Visiongain Publishes 3D Printing for Healthcare Market Report 2021-2031

The growing use of this technology in many applications such as transplantation, drug delivery, 3D printed organs, and many others in the healthcare industry is one of the key drivers in the global 3D Printing in Healthcare Market.

02 August 2021

READ

Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031

We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

29 July 2021

READ

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Categories